Evidence for systems that carry regulated work.
Source-backed reporting and analysis connected to the companies, capabilities, authorities, and operating domains it affects.
Kivo documents submission structures, content placeholders, a blinded-or-unblinded toggle, tracking spreadsheets, and export to publishing partners or software. A handoff still needs an approved content inventory, artifact-level blinding state, immutable transfer manifest, and receiver reconciliation before it can be treated as complete or appropriately disclosed.
Scilife describes controlled printing and reconciliation alongside its document-management workflows. A printed copy still needs a durable identity, point-of-use owner, issuance history, reconciliation state, and retirement evidence before teams can know which instruction was available for regulated work.
Generis presents CARA as one governed platform spanning regulatory, quality, safety, and clinical processes, with shared records and audit trails. The same underlying record can reduce re-entry, but each configured process still needs intended-use, migration, access, workflow, calculation, report, interface, and exception evidence before the organization can rely on it for regulated work.
EMA says the PLM web-based electronic Application Form becomes mandatory for human Centrally Authorised Product variation submissions on September 1, 2026, with justified technical exceptions for continued interactive-PDF use. Regulatory operations need to preserve the applicable form path, impediment, support evidence, submission package, and receipt outcome as separate controlled facts.
Dot Compliance presents Dottie as an AI quality and compliance guide within its life-sciences eQMS, alongside ready-to-use modules and quality workflows. Guidance may accelerate review, but the regulated record still needs attributable source evidence, qualified judgment, approval authority, and a preserved path from suggestion to decision.
Honeywell describes TrackWise PQR as automating Annual Product Quality Review work and TrackWise QMR as providing near-real-time metrics for management reviews. Connecting both can improve visibility, but a current metric, a periodic product review, and an authorized management conclusion answer different questions.
Ennov presents its Quality Suite as one application for managing and tracking quality documentation, processes, and data, with document management, quality management, and training in the suite. A unified record can make work visible and reviewable, but it does not by itself establish that a configured process was suitable, followed, or effective for its intended regulated use.
Qualio describes gap analysis, cross-mapped evidence, regulatory monitoring, and quality workflows in one platform. Reusing evidence can reduce duplicate work while each requirement still needs a current scope, implemented process, operating record, qualified review, and defensible conclusion.
Veeva describes a single cloud platform spanning quality assurance, quality control, and training. Connected records can reduce handoff friction without making a document approval, investigation conclusion, laboratory result, and training completion interchangeable.
A shared compliance environment can connect quality and regulatory work without turning a quality disposition into a registration decision—or a regulatory status into quality approval.
MasterControl documents configurable quality-event forms, rules-based routing, connected quality records, and AI-supported summaries and trend identification. Those functions can organize investigation, but the event, related change or training record, root-cause conclusion, and accountable disposition should remain separately evidenced.
The drug CGMP definitions connect a lot number to a batch or lot's complete manufacturing and distribution history. That identifier supports traceability, but it does not by itself show that acceptance criteria were met or that quality authorized release.
The finished-pharmaceutical CGMP rule connects qualification and continuing training to assigned functions and the operations a person performs. A completed annual course, learning-system badge, or attendance total does not by itself establish that qualification.
The guideline assigns the pharmaceutical company responsibility for controlling outsourced activities and purchased materials through prior assessment, written responsibilities, monitoring, and review.
The production-record rule connects quality-unit review, batch release, investigation beyond the first affected batch, written conclusions, and follow-up instead of allowing a passing final result to erase an unexplained event.
The pharmaceutical quality-system model connects a proposed change to risk-based evaluation before implementation and a check afterward that objectives were achieved without harming product quality.
Annex 11 requires formal responsibility boundaries when third parties support GMP computerised systems. A vendor package cannot substitute for the regulated user's lifecycle evidence.
Part 11 applies to specified electronic records and signatures in an FDA-regulated context. A system label cannot replace the first question: which record requirement, use, and retention obligation is in scope?
ICH Q9(R1) treats risk as a lifecycle decision process, including computerized systems. Buyers should test evidence, review triggers, and human authority.
The July release carries bug fixes and sits inside a broader transition toward structured application data, new MAA forms, and mandatory PLM web-based eAF use for centrally authorised product variations.
The July package refresh adds forward-compatibility samples and revises regional vocabulary, conformance, and transmission materials for a standard FDA already accepts for new applications.
The February guidance focuses assurance effort on software risk and confidence rather than prescribing one validation-document package, giving buyers a sharper way to examine vendor evidence and intended use.
The January transition changes classification and procedure rules for post-authorisation changes, forcing regulatory operations teams to align systems, forms, content, and implementation dates.
